Fig. 2From: Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts(Abstract 1) PCA analysis using T0 values of IL-5, IL-6, CD3+CD8+LAG3+, CD3+CD8+PD1+LAG3+ and CD8+TEMRA as parameters. Group B includes patients (n = 5) with factor 1 < 0.7 and factor 2 < 0; group A includes the other patients (n = 13). This Figure 2 belongs to Abstract 1Back to article page